Clinical trials
Refractory Non-Hodgkin Lymphoma clinical trials
Below are recruiting refractory non-hodgkin lymphoma clinical trials, each written for real people, not researchers. We’re tracking 186 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06223542RecruitingPhase 1
TAK-243 for advanced cancers that haven't responded to other treatments
This trial tests a new drug called TAK-243 for people with advanced cancers (solid tumors or lymphomas) that have not responded to other treatments. It aims to see if the drug is safe and how well it works.
Bethesda, MarylandAges 18 years+ - NCT05332054Enrolling by invitation
Long-term follow-up after prior Caribou treatment
This study checks your health over time after you previously took a Caribou medicine (or got it through a special access program). It helps researchers learn what happens in the longer run after the treatment.
Birmingham, AlabamaAges 18 years+ - NCT05963217RecruitingPhase 1
Study of a patient’s own CAR T cells for CD19 cancers
This Phase 1 study tests a personalized form of CAR T cell treatment made from your own immune cells to fight certain CD19-positive blood cancers that have returned or not responded to prior treatment. It mainly looks at safety and how well the treatment can work.
Toronto, OntarioAges 18 years+ - NCT04544592RecruitingPhase 1/Phase 2
CD19 CAR-T for children and young adults with B-cell blood cancers
This trial tests a one-time, lab-made immune cell treatment (CD19 CAR-T) for certain B-cell blood cancers in children and young adults. It may help people whose leukemia or lymphoma is not responding to standard treatment or has come back.
Aurora, ColoradoAges 1 month–30 years - NCT04771572RecruitingPhase 1
Oral drug LP-118 for relapsed blood cancers
This Phase 1 study tests an oral (by mouth) drug called LP-118 in people whose blood cancers have returned or did not respond to prior treatment. The goal is to find a safe dose and see whether it can shrink or control the cancer.
Chicago, IllinoisAges 13 years+ - NCT05702853RecruitingPhase 1/Phase 2
CAR T-cell therapy after CD34 selection for CD19 lymphoma or CLL
This Phase 1/2 study tests a customized type of immune cell treatment (CD19 CAR T-cells) for people with certain relapsed or hard-to-treat lymphomas or CLL/SLL. It aims to improve control of disease by targeting the CD19 marker on cancer cells.
Charleston, South CarolinaAges 18 years+ - NCT04288726RecruitingPhase 1
CAR T-cell trial for CD30-positive lymphomas that came back
This early-phase study tests a donor-made immune cell treatment designed to attack CD30-positive lymphomas that are relapsed or refractory. If you qualify, it could help by finding a safer, effective way to control the lymphoma using engineered T-cells.
Houston, TexasAges 12–75 - NCT06948786RecruitingPhase 2
Pirtobrutinib and Mosunetuzumab for relapsed follicular lymphoma
This trial tests two new drugs, pirtobrutinib and mosunetuzumab, for people with follicular lymphoma that has come back or not responded to earlier treatments. The goal is to see if this combination can help control the cancer.
Seattle, WashingtonAges 18 years+ - NCT05476770RecruitingPhase 1
Tagraxofusp for children with CD123-positive leukemia
This study tests tagraxofusp, a medicine that targets a marker called CD123 on cancer cells, in children and young adults whose leukemia or lymphoma has come back or is resistant to treatment. It may help by shrinking the cancer and improving disease control after standard therapies have not worked.
Los Angeles, CaliforniaAges 1–21 - NCT06918912RecruitingPhase 2
Loncastuximab tesirine for lymphoma after CAR-T therapy
This trial tests a drug called loncastuximab tesirine for people with diffuse large B-cell lymphoma or high-grade B-cell lymphoma that has come back or not responded after CAR-T cell therapy. It aims to see if the drug can help when other treatments have stopped working.
Alessandria, ALESSANDRIAAges 18–99 - NCT05681195RecruitingPhase 2
Zanubrutinib plus pemetrexed for recurrent brain lymphomas
This trial tests zanubrutinib (a targeted lymphoma medicine) together with pemetrexed (chemotherapy) for lymphoma that has come back or did not respond well in or around the brain. It may help shrink measurable lymphoma and improve control of disease after prior treatments.
Miami, FloridaAges 18 years+ - NCT06651853RecruitingPhase 2
Radiation therapy with lenalidomide and glofitamab for DLBCL
This trial tests a combination of radiation therapy, lenalidomide, and glofitamab for people with a type of lymphoma called DLBCL that has not responded to or has returned after initial treatment. The goal is to see if this combination can help when other treatments have failed.
Xiamen, FujianAges 18 years+ - NCT07284433RecruitingPhase 1/Phase 2
Donor cell therapy for B-cell blood cancers
This trial tests a new treatment made from donor cells that target two proteins (CD19 and CD20) found on certain blood cancer cells. It may be an option for people whose B-cell lymphoma or chronic lymphocytic leukemia has come back or hasn't responded to at least two prior treatments.
Chicago, IllinoisAges 18 years+ - NCT04993690RecruitingPhase 1
Oral LP-168 for relapsed or hard-to-treat B-cell lymphoma
This Phase 1 study tests whether an oral medicine called LP-168 can be given safely and possibly work against lymphoma that has come back or is not responding to standard treatment. It’s mainly looking for safety, but your results could help determine whether the drug should be studied further.
Beijing, Beijing MunicipalityAges 18–80 - NCT04792489RecruitingPhase 2
CAR-T cell therapy for aggressive B-cell lymphomas
This trial tests a new CAR-T cell treatment (MB-CART2019.1) for people with certain types of aggressive B-cell non-Hodgkin lymphoma, including diffuse large B-cell lymphoma (DLBCL) that has come back or not responded to prior treatments. It aims to see if this therapy can help when other options have failed.
Birmingham, AlabamaAges 18 years+ - NCT06961669Recruiting
CD19 CAR-T cells for B-cell cancers and multiple myeloma
This trial tests a personalized treatment where your own immune cells are modified to target and kill cancer cells that have a protein called CD19. It is for patients with certain types of B-cell lymphoma, B-cell acute leukemia, or multiple myeloma that has come back or not responded to previous treatment.
HefeiAges 3 years+ - NCT05544968RecruitingPhase 1
CD30-targeted cell treatment for hard-to-treat blood cancers
This Phase 1 trial studies an experimental treatment that targets a marker called CD30 on cancer cells. It is for adults with certain relapsed or refractory CD30-positive blood cancers to see how well the treatment works and what side effects it causes.
Milwaukee, WisconsinAges 18 years+ - NCT05091424RecruitingPhase 1
Mosunetuzumab with or without venetoclax for CLL
This Phase 1 study tests whether mosunetuzumab alone or with venetoclax is safe and effective for people with chronic lymphocytic leukemia (CLL) that came back or did not respond to prior treatment. It may help by controlling the CLL immune system response while also studying dosing and side effects.
Rochester, MinnesotaAges 18 years+
Hear when a new Refractory Non-Hodgkin Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for refractory non-hodgkin lymphoma?
- Yes. Clin2 currently lists 186 recruiting refractory non-hodgkin lymphoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a refractory non-hodgkin lymphoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a refractory non-hodgkin lymphoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Refractory B-Cell Non-Hodgkin Lymphoma
- Non-Hodgkin Lymphoma Refractory/ Relapsed
- Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
- Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
- Refractory Indolent Non-Hodgkin Lymphoma
- Refractory Transformed B-cell Non-Hodgkin Lymphoma
- Refractory Transformed Non-Hodgkin Lymphoma
- Non-Hodgkin Lymphoma
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.